You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
永勝醫療(01612.HK)收入及盈利創新高 中期純利升606.5% 毛利率升至44.9%
格隆匯 08-25 16:50

格隆匯8月25日丨永勝醫療(01612.HK)發佈公告,截至2020年6月30日止6個月,公司收入及盈利能力雙雙創出新高,收入增加103.8%至5.02億港元,而呼吸產品收入增加249.5%至3.63億港元。原品牌製造(OBM)及原設備製造(OEM)兩個分部的收入均錄得強勁的內部自然增長,分別增長313.8%及35.2%。OBM分部成為主要收入貢獻來源,佔2020年上半年收入的比例略高於50.0%,並首次帶來溢利貢獻達7700萬港元。

期間毛利增加169.2%至2.25億港元,整體毛利率上升10.9個百分點至44.9%;純利躍升606.5%至1.1億港元,純利率上升15.5個百分點至21.8%;每股基本盈利上升572.9%至14.40港仙。

期間用於治療2019冠狀病毒病的電子器械銷售增長強勁。inspired VHB系列加濕器和inspired O2FLO呼吸濕化治療儀的銷量分別達95,572台和4,306台。公司各種呼吸類耗材的產能已提升三倍。

展望未來,永勝醫療將通過推出新器械以及從專用耗材獲得經常性收入,繼續推行器械+耗材的發展戰略。疫情在全球大流行,令高流量氧療成為呼吸衰竭治療手法中的焦點;加上高流量氧療是可用於治療2019冠狀病毒病以外的多項呼吸相關疾病,因此其潛力尚未完全顯現。公司預計醫院將加快採用高流量氧療並擴大其使用範圍,同時此療法在未來很大可能適合在家居使用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account